LONGEVA.

Thymosin beta-4: adverse events in a trial

The abstract of a synthetic thymosin beta-4 trial describes 40 healthy volunteers, intravenous exposure and a repeated 14-day course. Adverse events were infrequent and mild or moderate; no serious events or dose-limiting toxicity were reported. [1]

The abstract gives no event-specific frequencies. This short intravenous trial does not establish lasting risks or safety of a particular reagent batch, the TB-500 fragment or blends. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events overall40 healthy volunteers, intravenous synthetic thymosin beta-4, single dose and a repeated 14-day courseWere infrequent and mild or moderate; the abstract gives no event-specific frequencies[1]
Serious events and dose-limiting toxicityThe same volunteersNone reported[1]

References

  1. Ruff D et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.